Effectiveness and safety of apixaban and rivaroxaban vs warfarin in patients with atrial fibrillation and chronic kidney disease

Table 3 E-values for significant comparisons in an on-treatment analysis after inverse probability of treatment weighting of new oral anticoagulant users with stage III chronic kidney disease

	Hazard ratio (95%CI)	E value corresponding to the CI bound closest to 1	E value for hazard ratio point estimate1
Apixaban 2.5 mg vs warfarin
Safety composite	0.65 (0.43-0.99)	1.11	2.45
Apixaban 5.0 mg vs warfarin
Effectiveness composite	0.76 (0.65-0.88)	1.53	1.96
All-cause mortality	0.61 (0.43-0.88)	1.53	2.66

¹E-value for hazard used the point estimate instead of the bound closest to 1.

CI: Confidence interval.